07/09/2023 ET
PREVYMIS (Letermovir) $默沙东(MRK)$ $109.84
PDUFA date is expected on September 7, 2023.
网页链接{U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk | Business Wire}
09/09/2023 ET
Motixafortide (BL-8040) - (GENESIS) $BioLineRx(BLRX)$ $2.02
PDUFA target action date set for September 9, 2023. NDA accepted, noted November 10, 2022.
网页链接{BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (prnewswire.com)}
15/09/2023 ET
TECENTRIQ (atezolizumab) using ENHANZE - (IMscin001) $奥洛兹美疗法(HALO)$ $42.82 , RHHBY $36.52
PDUFA planned for September 15, 2023.
网页链接{Inline XBRL Viewer (sec.gov)}